Breaking the LSD1/KDM1A Addiction: Therapeutic Targeting of the Epigenetic Modifier in AML

被引：46
|
作者：
Lokken, Alyson A. [1 ]
Zeleznik-Le, Nancy J. [1 ,2 ]
机构：
[1] Loyola Univ Chicago, Inst Oncol, Maywood, IL 60153 USA
[2] Loyola Univ Chicago, Dept Med, Maywood, IL 60153 USA
来源：
CANCER CELL | 2012年 / 21卷 / 04期
关键词：
LSD1; COMPLEXES; PROTEINS;
D O I：
10.1016/j.ccr.2012.03.027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
KDM1A/LSD1, a histone H3K4/K9 demethylase and epigenetic regulator with roles in both gene activation and repression, has increased expression in multiple cancer types. Harris et al., in this issue of Cancer Cell, and Schenk et al. show that KDM1A may be a viable therapeutic target in treating AML.
引用
收藏
页码：451 / 453
页数：3
相关论文
共 50 条
  • [31] Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
    W Fiskus
    S Sharma
    B Shah
    B P Portier
    S G T Devaraj
    K Liu
    S P Iyer
    D Bearss
    K N Bhalla
    Leukemia, 2014, 28 : 2155 - 2164
  • [32] Discovery of natural product-like spirooxindole derivatives as highly potent and selective LSD1/KDM1A inhibitors for AML treatment
    Yang, Chao
    Fang, Yuan
    Luo, Xiang
    Teng, Dehong
    Liu, Zhongqiu
    Zhou, Yingtang
    Liao, Guochao
    BIOORGANIC CHEMISTRY, 2022, 120
  • [33] Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib
    Zong, Yi
    Tao, Zhigang
    Jiang, Siyi
    Wang, Minyuan
    Yu, Weihua
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [34] KDM1A/LSD1 as a promising target in various diseases treatment by regulating autophagy network
    Ma, Ting
    Li, Anqi
    Guo, Yueyang
    Li, Shaotong
    Li, Meng
    Feng, Siqi
    Liu, Hongmin
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 148
  • [35] Somatic deletion of KDM1A/LSD1 gene is associated to advanced colorectal cancer stages
    Ramirez-Ramirez, Ruth
    Gutierrez-Angulo, Melva
    Peregrina-Sandoval, Jorge
    Miguel Moreno-Ortiz, Jose
    Antonio Franco-Topete, Ramon
    de Jesus Cerda-Camacho, Felipe
    de la Luz Ayala-Madrigal, Maria
    JOURNAL OF CLINICAL PATHOLOGY, 2020, 73 (02) : 107 - 111
  • [36] Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
    Fiskus, W.
    Sharma, S.
    Shah, B.
    Portier, B. P.
    Devaraj, S. G. T.
    Liu, K.
    Iyer, S. P.
    Bearss, D.
    Bhalla, K. N.
    LEUKEMIA, 2014, 28 (11) : 2155 - 2164
  • [37] LSD1: biologic roles and therapeutic targeting
    Maiques-Diaz, Alba
    Somervaille, Tim C. P.
    EPIGENOMICS, 2016, 8 (08) : 1103 - 1116
  • [38] Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A
    Cuyas, Elisabet
    Gumuzio, Juan
    Lozano-Sanchez, Jesus
    Carreras, David
    Verdura, Sara
    Llorach-Pares, Laura
    Sanchez-Martinez, Melchor
    Selga, Elisabet
    Perez, Guillermo J.
    Scornik, Fabiana S.
    Brugada, Ramon
    Bosch-Barrera, Joaquim
    Segura-Carretero, Antonio
    Martin, Angel G.
    Antonio Encinar, Jose
    Menendez, Javier A.
    NUTRIENTS, 2019, 11 (07)
  • [39] Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis
    Gill, Harinder
    CELLS, 2022, 11 (13)
  • [40] Erratum: Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
    W Fiskus
    S Sharma
    B Shah
    B P Portier
    S G T Devaraj
    K Liu
    S P Iyer
    D Bearss
    K N Bhalla
    Leukemia, 2017, 31 : 1658 - 1658
12345